LONDON, Feb. 10, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Dr. Stephen Wright, GW's Director of Research and Development, is scheduled to present at the Leerink Global Healthcare Conference on Wednesday, 12 February, 2014 at 3:30 p.m. ET. The conference will be held at the Waldorf Astoria Hotel in New York City.
A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet syndrome, a severe infantile-onset, genetic, drug-resistant epilepsy syndrome. Our product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.
|GW Pharmaceuticals plc||(Today) + 44 20 7831 3113|
|Justin Gover, Chief Executive Officer||(Thereafter) + 44 1980 557000|
|Stephen Schultz, VP Investor Relations (US)||+ 1 401 500 6570|
|FTI Consulting (Media Enquiries)|
|Ben Atwell / Simon Conway / John Dineen (UK)||+ 44 20 7831 3113|
|Robert Stanislaro (US)||+1 212 850 5657|
|Trout Group, LLC (US investor relations)|
|Todd James / Chad Rubin||+1 646 378 2900|
Source:GW Pharmaceuticals plc